E
Enlaza Therapeutics
A biotechnology research company
About Enlaza Therapeutics
Enlaza Therapeutics, founded by Dr. Duron, is a trailblazer in the field of covalent biologics. The company is focused on developing a new generation of protein therapeutics using its proprietary platform. These innovative treatments are designed to be more effective and safer for patients, offering a significant advancement in the biotech industry.
The company operates in the biotech market, specifically in the area of therapeutic proteins and biologics. Its target clients are primarily patients who can benefit from their novel therapies. The business model of Enlaza revolves around the development, production, and distribution of these cutting-edge protein therapeutics.
Dr. Duron, with his extensive experience in venture-backed biotech and a history of successful acquisitions, leads the company. He is supported by a team of seasoned biopharmaceutical professionals, including Lei Wang, a renowned professor in the field of pharmaceutical chemistry.
Enlaza generates revenue through the commercialization of its innovative protein therapeutics. The company's financial health is likely to be bolstered by the high demand for more effective and safer treatments in the healthcare sector.
In summary, Enlaza Therapeutics is a pioneering biotech company with a focus on developing novel protein therapeutics. It is led by a team of experienced professionals and operates in a market with high growth potential.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Sep 2025 | $0 | — | Undisclosed | — |
| SERIES AOther financing | Apr 2024 | $100M | $400M | Lightspeed Venture Partners · Avalon Ventures · Pappas Capital · Samsara BioCapital | ↗ |
Growth signals
Latest recorded traffic for Enlaza Therapeutics is 2K monthly website visits, down 4.8% over the last three months. Enlaza Therapeutics's team grew 11.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Enlaza Therapeutics in the San Diego ecosystem
The Enlaza Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Avalon BioVentures
Lightspeed Venture Partners
Avalon Ventures
Samsara BioCapital- FCFrazier Lifesciences Acquisition Corporation
Series A7 investors entered at this stage
J.P. Morgan Asset Management
Pappas Capital
Frazier Life Sciences
Amgen Ventures
Alexandria Venture Investments- BCBregua Corporation
Regeneron Ventures
Other known investors2 additional known investors
Scripps Translational Science Institute
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Enlaza Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Enlaza Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










